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license (http://creativeDefects in monoamine neurotransmitter systems are implicated in DS and AD but have not been
comprehensively studied in DS.
Methods: Noradrenaline, adrenaline, and their metabolite 3-methoxy-4-hydroxyphenylglycol
(MHPG); dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid; and serotonin and its metabolite 5-hydroxyindoleacetic acid were quantified in 15 brain regions
of DS without AD (DS, n 5 4), DS with AD (DS1AD, n 5 17), early-onset AD (EOAD, n 5 11)
patients, and healthy non-DS controls (n5 10) in the general population. Moreover, monoaminergic
concentrations were determined in cerebrospinal fluid (CSF)/plasma samples of DS (n5 37/149), DS
with prodromal AD (DS1pAD, n 5 13/36), and DS1AD (n 5 18/40).
Results: In brain, noradrenergic and serotonergic compounds were overall reduced in DS1AD
versus EOAD, while the dopaminergic system showed a bidirectional change. For DS versus
non-DS controls, significantly decreased MHPG levels were noted in various brain regions, though
to a lesser extent than for DS1AD versus EOAD. Apart from DOPAC, CSF/plasma concentrations
were not altered between groups.
Discussion: Monoamine neurotransmitters and metabolites were evidently impacted in DS, DS1AD,
and EOAD.DS andDS1ADpresented a remarkably similar monoaminergic profile, possibly related to
early deposition of amyloid pathology inDS. To confirmwhether monoaminergic alterations are indeed
due to early amyloid b accumulation, future avenues include positron emission tomography studies of
monoaminergic neurotransmission in relation to amyloid deposition, as well as relatingmonoaminergic
concentrations to CSF/plasma levels of amyloid b and tau within individuals.
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People with Down syndrome (DS), or trisomy 21, have an
exceptionally high risk to develop Alzheimer’s disease
(AD): 68%–80% of people are diagnosed with dementia
by the age of 65 years [1]. The additional copy of chromo-
some 21, encoding the amyloid precursor protein (APP),
causes overproduction of amyloid b (Ab) peptides. Very
early in life, intracellular Ab accumulation takes place in
neurons, followed by extracellular Ab aggregation and
subsequent deposition in characteristic Ab plaques [2–5].
In DS brains, not only plaques but also neurofibrillary
tangles are omnipresent from the age of 40 years [6]. The
onset of clinical dementia symptoms, however, is subject
to a marked variation in time [7,8]. Because the dementia
diagnosis in DS is complex, among others due to
comorbidities, pre-existing intellectual disability, and
behavior [9], sensitive and specific biomarkers for AD in
DS would be very valuable. In the general non-DS popula-
tion, the so-called “AD profile” (low Ab42, high total-tau,
and high phosphorylated-tau) in cerebrospinal fluid (CSF)
has proven useful as a diagnostic aid [10]. However, the
clinical utility in DS has not been demonstrated yet [11].
Therefore, the study of alternative biomarkers for AD in
DS receives vast attention.
In this context, we previously analyzed monoamine
neurotransmitters and metabolites in serum of 151 elderly
DS individuals with AD (DS1AD) and without AD (DS),
but also in a nondemented DS group at blood sampling
that developed dementia over time (converters). Remark-
ably, serum levels of the primary noradrenergic metabolite
3-methoxy-4-hydroxyphenylglycol (MHPG) were strongly
decreased in DS1AD, but also in converted DS individuals.
Individuals with MHPG levels below median had a more
than 10-fold increased risk of developing dementia, suggest-
ing that decreased serumMHPG levels may be predictive for
conversion to AD [12].
Blood biomarkers, however, are subject to (confounding)
peripheral effects. CSF biomarkers are generally regarded
better indicators of biochemical changes in the central
nervous system because of their direct contact with the extra-
cellular space [13]. Very few studies have investigated
CSF biomarkers in (moreover small) DS cohorts [11],
including two on monoamines [14,15]. Although a few
postmortem studies were conducted several decades ago, a
comprehensive profile of central monoaminergic changes
in DS1AD is not established yet. Indeed, monoamines
were quantified in a limited number of brain regions from
a few DS cases with often long postmortem delays
(PMDs). For instance, cell loss in the locus coeruleus
(LC), major source of noradrenaline (NA), and reduced
NA concentrations have been reported in elderly DS cases
[16–23], but an integrated study of regional changes in
NA, dopamine (DA), serotonin (5-HT), and their primary
metabolites is lacking. Vermeiren et al., for example, inves-
tigated monoaminergic profiles in a variety of postmortembrain regions in early-onset AD patients (EOAD) compared
with age- and gender-matched control subjects. In EOAD
patients, lower levels of serotonergic compounds were found
in amygdala and hippocampus, complemented by lower NA
levels in the prefrontal cortex and amygdala. No differences
in MHPG levels could be observed [24].
To the best of our knowledge, this study is the first to
comprehensively evaluate monoaminergic alterations in (1)
postmortem brain tissues and (2) (paired) CSF/plasma
samples from DS individuals with and without AD. Norad-
renergic (NA; adrenaline; MHPG), dopaminergic (DA; 3,4-
dihydroxyphenylacetic acid [DOPAC]; homovanillic acid
[HVA]), and serotonergic (5-HT; 5-hydroxyindoleacetic
acid [5-HIAA]) compounds were quantified using reversed
phase high-performance liquid chromatography (RP-HPLC).
In one of the largest collections of DS brain tissue
(n 5 21), 15 regions of DS cases without and with a neuro-
pathologically confirmed diagnosis of AD (DS and
DS1AD, respectively) were analyzed and compared with
EOAD patients and healthy controls in the general popula-
tion. Second, we report the monoaminergic results in
(paired) CSF/plasma samples obtained from the largest DS
cohort to have undergone lumbar punctures, comparing DS
without dementia (DS), DS with prodromal AD (DS1pAD),
and DS with clinically diagnosed AD (DS1AD).2. Materials and methods
2.1. Postmortem samples2.1.1. Study population
In total, postmortem samples from 21 elderly DS individ-
uals were obtained from the Netherlands Brain Bank (NBB),
Netherlands Institute for Neuroscience (Amsterdam, The
Netherlands), the Neurological Tissue Bank—Biobanc,
Hospital Clinic Barcelona—Institut d’Investigacions
Biomediques August Pi i Sunyer (IDIBAPS; Barcelona,
Spain), and the Institute Born-Bunge (IBB; Antwerp,
Belgium). Specifically, brain samples from nine DS1AD in-
dividuals were obtained from the NBB (open access: www.
brainbank.nl). All material has been collected from donors
for or from whom written informed consent for a brain au-
topsy and the use of the material and clinical information
for research purposes had been obtained by the NBB.
Moreover, the IDIBAPS provided samples of two DS and
five DS1AD donors for whom written informed consent
was obtained from the next of kin. The study was approved
by the Hospital Clinic de Barcelona Ethics Committee and
in accordance with Spanish legislation. Finally, the IBB
provided samples of DS (n5 2), DS1AD (n5 3), EOAD pa-
tients (n 5 11), and healthy controls without neurological
disease (n 5 10). Since DS1AD presents early in life, we
identified EOAD patients and controls ,75 years of age as
comparison groups. Ethical approval was granted by the
medical ethics committee of the Hospital Network Antwerp
Table 1
Characteristics of postmortem study groups
Characteristics DS (n 5 4) DS1AD (n 5 17) EOAD (n 5 11) Controls (n 5 10) P value
Age at death in years (median; min.2max.) 39.5 (35.0–44.0)a,b,c 62.0 (44.0–80.0)a 67.2 (57.6–73.0)b 65.5 (57.2–73.3)c .004
Gender (N male and %) 2 (50) 5 (29.4) 8 (72.7) 6 (60) n.s.
Psychoactive medication (yes/no/not reported) 3/0/1 10/3/4 3/8/0 2/8/0 .002
Postmortem delay in hours (median; min.–max.) 21.0 (11.5–36.0)a,b,c 7.3 (3.8–20.0)a,b,e 3.0 (2.8–7.0)b,d 5.4 (2.3–7.0)c,e ,.001
AD neuropathologic change Low High Intermediate (1)/High (10) Not (6)/Low (4)
Available brain regions per study group
Neocortex
BA7: superior parietal lobule 2 13 11 10
BA9/10/46: (pre)frontal cortex 4 14 11 10
BA17: occipital pole (V1) 3 7 11 10
BA22: superior temporal gyrus 3 10 11 10
Limbic system
Amygdala 2 10 10 10
Hippocampus 3 5 11 10
BA11/12: orbitofrontal cortex 4 6 11 10
Cingulate gyrus 3 8 11 10
Thalamus 3 11 11 10
Basal ganglia
Caudate nucleus 3 16 11 10
Globus pallidus 2 8 11 10
Putamen 3 15 11 10
Substantia nigra 2 14 11 10
Metencephalon
Locus coeruleus (in pons) – 10 10 10
Cerebellar cortex 2 9 10 10
Abbreviations: AD, Alzheimer’s disease; BA, Brodmann area; DS, Down syndrome without neuropathologic AD diagnosis; DS1AD, Down syndrome with
neuropathologic AD diagnosis; EOAD, early-onset Alzheimer’s disease; n.s., not significant.
NOTE. Gender and medication use were compared with Fisher’s exact test. Kruskal-Wallis tests were performed to compare ages and postmortem delays
between the groups. Post hoc Mann-Whitney U tests were performed to identify significant group differences (P , .015): (a) DS vs. DS1AD; (b) DS vs.
EOAD; (c) DS vs. controls; (d) DS1AD vs. EOAD; (e) DS1AD vs. controls.
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2.1.2. Assessment of AD neuropathologic changes
Neuropathological analysis was conducted according to
the “ABC scoring” system [25]. Formalin-fixed paraffin-
embedded samples were sectioned in concordance with the
minimally recommended brain regions (if available). If
possible, additional sections of the cingulate gyrus, amygdala,
pons at the level of the LC, and medulla oblongata were
included. Applied stains were hematoxylin-eosin, cresyl
violet, Kl€uver-Barrera (myelin), and modified Bielschowsky
silver staining. Moreover, antibodies against amyloid (4G8),
phosphorylated-tau (AT8), ubiquitin, TDP-43, and p62 Lck li-
gands were used. All cases were diagnosed by experienced
neuropathologists (E.G., A.S., and J.-J.M.) as not, low, inter-
mediate, or high AD neuropathologic changes. Intermediate
and high signify the diagnosis of AD [25].
2.1.3. Regional brain samples and dissection
Table 1 shows the selection of frozen samples for RP-
HPLC analyses. Brains were included in the three biobanks
between 1990 and 2011 and stored at 280C. Postmortem
delays: NBB (,10 hours), IDIBAPS (,12 hours), andIBB (DS: 20 and 36 hours; DS1AD: 15 hours, 20 hours,
and one unknown; and EOAD/controls:,7 hours). Samples
were dissected from the left hemispheres (undefined hemi-
sphere for three IBB cases). Not all regions were available
for all cases. Most samples from EOAD and controls have
been published before [24]. For this study, Brodmann area
(BA)7, substantia nigra (SN), caudate nucleus, globus pal-
lidus, and putamen were additionally analyzed.2.2. CSF/plasma samples
Samples of 241 DS adults were obtained from the Down
Alzheimer Barcelona Neuroimaging Initiative study, a pro-
spective biomarker study for AD in DS [26–28]. The
person with DS and/or the legal representative provided
written informed consent. The study was compliant with
the World Medical Association Declaration of Helsinki on
Ethical Principles for Medical Research Involving Human
Subjects and approved by the ethics committee of the Sant
Pau hospital in Barcelona [27]. Neurologists and neuropsy-
chologists established a consensus diagnosis of dementia,
distinguishing between DS without dementia (DS), DS
with prodromal AD (DS1pAD), and DS with diagnosed
AD (DS1AD). Specifically, the DS group did not show ev-
idence of cognitive decline. The DS1pAD group includes
individuals who (1) presented cognitive/functional change
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nificant cognitive decline in longitudinal assessment. The
DS1AD group includes individuals with clear cognitive/
functional change meeting the dementia criteria (IWG-2
[29]). In the diagnostic procedure, medical comorbidities
and other possible causes of cognitive decline were assessed
(differential diagnostics). DS cases with cognitive decline
due to medical comorbidities or a psychiatric etiology
were excluded (Fig. 1). Use of psychoactive medication
around the moment of sampling was noted. Within the
Down Alzheimer Barcelona Neuroimaging Initiative study,
participants are offered a lumbar puncture, which was found
to be feasible and safe [27]. For 68 individuals, paired CSF/
plasma samples were obtained. The other 157 participants
provided plasma-only. CSF and plasma samples were drawn
on the same day. Lumbar punctures were performed between
9 and 12 am, directly followed by plasma collection. Sam-
ples were stored at 280C.2.3. Reversed-phase HPLC
To quantify noradrenergic (NA; adrenaline; MHPG),
dopaminergic (DA; DOPAC; HVA), and serotonergic
(5-HT; 5-HIAA) compounds, a validated RP-HPLC setup
with ion pairing (octane-1-sulfonic acid sodium salt) and
amperometric electrochemical detection was used [30], previ-
ously applied to CSF and blood samples [12] and brain
homogenates [24,31–33]. Concentrations were calculatedFig. 1. Flow chart of CSF/plasma study groups. Abbreviations: AD, Alzheimer’
dementia; DS1AD, DS with diagnosed AD dementia; DS1pAD, Down syndromusing Clarity Software (DataApex Ltd., 2008, Prague,
Czech Republic).2.4. Statistics
Histograms, normal quantile-quantile (Q-Q) plots, and
Shapiro-Wilk tests (P, .05) demonstrated that the concentra-
tions in the brain and CSF/plasma were (largely) not normally
distributed. Consequently, nonparametric Kruskal-Wallis tests
were applied to compare groups. If the P value was,.05, post
hocMann-WhitneyU tests were conducted. In brain, the three
most relevant group comparisons were performed: DS versus
DS1AD, DS1AD versus EOAD, and DS versus controls.
The EOAD versus controls comparison has been largely
published before [24]. Regarding CSF/plasma samples, we
analyzed the total cohort (n 5 225), that is, all individuals
regardless of medication use, as well as the medication-free
subpopulation because psychoactive medication may affect
monoaminergic neurotransmission. Nonparametric Spear-
man’s rank-order correlation tests established the relationship
with age and between CSF and plasma concentrations. Cohort
characteristics like gender and medication use were compared
using Pearson’s c2 tests or Fisher’s exact tests. To account for
multiple comparisons, we applied the Benjamini-Hochberg
procedure with a false discovery rate of 0.05 [34]. Original
P values ,.015 were regarded significant. Finally, we evalu-
ated whether the results in the brain were possibly affected
by psychoactive medication and PMDs. Within each group,
we performed Mann-Whitney U tests to compares disease; CSF, cerebrospinal fluid; DS, Down syndrome without (clinical)
e with prodromal AD.
Fig. 2. MHPG concentrations (ng/g tissue) for each study group in neocortical areas, the limbic system, locus coeruleus, and cerebellum. The boxes represent
the IQR (25%–75%) with the black horizontal line indicating the median. The whiskers indicate values within 1.5 IQR. Mild outliers (1.5–3 IQR) are indicated
with an open circle, whereas extreme outliers (.3 IQR) with an asterisk. One extreme value (EOAD,MHPG concentration in hippocampus of 3806 ng/g tissue)
is not shown with respect to scaling. Evidently, MHPG levels were consistently lower in DS (vs. controls) and DS1AD (vs. EOAD). DS vs. DS1AD did not
differ significantly. Individual comparison statistics are provided in Table 2. Abbreviations: BA, Brodmann area; DS, Down syndromewithout neuropathologic
AD diagnosis; DS1AD, Down syndrome with neuropathologic AD diagnosis; EOAD, early-onset Alzheimer’s disease; IQR, interquartile range; MHPG,
3-methoxy-4-hydroxyphenylglycol.
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active medication and a subgroup that did not and performed
Spearman’s rank-order correlation tests to establish the associ-
ation between PMDs and monoaminergic concentrations.
IBM SPSS Statistics, version 23.0, was used.3. Results
Based on the measured concentrations, five accompa-
nying ratios were calculated: (1) MHPG:NA (noradrenergic
turnover), (2) DOPAC:DA (dopaminergic turnover) and
(3) HVA:DA (dopaminergic turnover), (4) 5-HIAA:5-HT
(serotonergic turnover), and (5) HVA:5-HIAA (serotonergic
inhibition on dopaminergic neurotransmission).3.1. Monoaminergic characterization of postmortem brain
tissue
Table 1 shows the general demographics, use of psycho-
active medication, and PMDs for each of the four groups.
Table 2 provides the monoaminergic concentrations (median
and quartiles) that differed significantly between the groups.
Specifically, DS versus DS1AD, DS1AD versus EOAD,
and DS versus controls were compared. EOAD and controls
were used as the reference group (compared in [24], thus
not further described here). The supplementary material
provides all concentrations and the accompanying
ratios for noradrenergic (Supplementary Table 1), dopami-nergic (Supplementary Table 2), and serotonergic
(Supplementary Table 3) systems.
Since psychoactive medication may affect monoamin-
ergic concentrations, we assessed the donors’ clinical
documentation (Table 1). Comparing individuals who did
and did not use psychoactive medication within each group
yielded no significant monoaminergic differences in
DS1AD and control groups, whereas only a single signifi-
cant difference was found in the EOAD group: NA levels
in the caudate nucleus were lower in individuals using medi-
cation (P 5 .014). In the DS group, the effect of medication
could not be established: three in four used medication, and
for the last person, it was unknown. Nevertheless, the use of
psychoactive medication did not appear to have evidently
impacted monoaminergic concentrations in DS1AD,
EOAD, and control groups.
Given the very limited availability of postmortem DS tis-
sue, it was impossible to select for short PMDs, particularly
in the DS group. Apart from three cases, PMD was
,12 hours in the DS1AD group. Because PMDs differed
between groups (Table 1), we subsequently examined
whether PMD was associated with monoaminergic concen-
trations. Spearman’s rank-order correlation tests within each
group revealed few significant associations with PMDs:
HVA (cingulate gyrus, r520.90, P5 .002) in the DS1AD
group; MHPG (caudate nucleus, r5 0.85, P5 .001 and SN,
r5 0.91, P, .001), DA (BA11/12, r5 0.74, P5 .01), HVA
(BA9/10/46, r 5 0.80, P 5 .003; BA22, r 5 0.88, P , .001;
Table 2
Comparison of postmortem concentrations between the groups
Brain region Compound N
DS
(n 5 4)
DS1AD
(n 5 17)
EOAD
(n 5 11)
Controls
(n 5 10) P value
Neocortex
BA7 MHPG 2/13/11/10 71.0 (63.3–) 72.3 (57.0–105.2)* 119.4 (106.0–189.5)* 259.7 (119.8–354.5) ,.001
DA 2/12/11/10 11.0 (6.5–) 18.7 (12.5–28.7) 10.7 (6.4–16.5) 6.9 (4.5–9.9) .004
5-HIAA 2/13/11/10 92.8 (70.4–) 40.2 (30.4–71.1) 55.3 (40.5–93.7) 106.4 (75.3–158.9) .003
BA9/10/46 MHPG 4/14/11/10 84.2 (77.7–86.9) 107.4 (63.4–133.8)** 471.2 (284.3–655.1)** 265.7 (132.4–629.6) ,.001
DA 4/14/11/10 127.5 (11.4–497.4) 373.9 (204.3–743.6)** 7.2 (2.5–9.3)** 7.5 (4.0–11.3) ,.001
5-HT 4/14/11/10 17.8 (13.2–30.6) 28.7 (15.3–49.8)* 11.1 (6.1–15.0)* 11.7 (7.4–16.7) .009
5-HIAA 4/14/11/10 81.1 (64.6–122.2) 62.2 (33.9–87.4)* 144.7 (110.5–186.6)* 164.1 (128.2–215.6) .001
BA17 MHPG 3/7/11/10 77.2 (61.3–)# 89.2 (73.6–114.6) 127.9 (101.6–182.0) 285.3 (244.0–530.1)# ,.001
5-HIAA 3/7/11/10 126.0 (93.6–) 92.1 (46.9–144.1) 95.6 (57.5–143.6) 200.8 (154.3–263.9) .008
BA22 NA 3/10/9/10 30.2 (18.3–) 17.3 (12.5–27.4) 10.0 (7.4–12.4) 18.7 (13.6–28.5) .014
MHPG 3/10/11/10 107.3 (80.4–)# 87.0 (60.0–125.4)** 520.7 (313.4–673.4)** 360.5 (260.4–630.7)# ,.001
DA 3/10/11/10 6.7 (6.5–) 11.3 (8.1–25.2)* 4.2 (3.2–6.8)* 9.1 (5.4–18.4) .041
5-HIAA 3/10/11/10 119.1 (98.7–) 84.0 (60.4–131.7)* 303.2 (119.6–450.2)* 171.5 (121.7–320.6) .004
Limbic system
Amygdala NA 2/10/10/10 21.8 (19.5–) 25.3 (13.6–39.8)* 59.0 (46.9–78.5)* 84.5 (77.5–121.8) ,.001
MHPG 2/10/10/10 68.8 (58.2–) 70.9 (62.5–94.9)** 429.8 (180.0–964.3)** 304.8 (193.5–759.3) ,.001
HVA 2/10/10/10 265.8 (174.5–) 376.2 (258.9–617.2) 599.1 (398.7–866.2) 1132.5 (751.0–1421.4) .005
5-HT 2/10/10/10 59.3 (11.7–) 33.0 (18.6–49.6)* 121.1 (55.1–148.6)* 244.9 (221.7–297.2) ,.001
5-HIAA 2/10/10/10 197.9 (162.9–) 141.3 (102.8–227.1)** 522.4 (334.9–795.2)** 999.8 (754.5–1270.4) ,.001
Hippocampus Adrenaline 2/5/3/5 391.6 (236.5–) 42.3 (20.6–139.0) 6.4 (2.6–) 10.1 (6.4–14.1) .011
MHPG 3/5/11/10 75.9 (70.3–)# 97.2 (76.9–124.8)** 459.5 (193.2–1099.2)** 416.3 (232.9–713.5)# ,.001
5-HT 3/5/11/10 46.6 (28.0–) 13.5 (8.6–50.0) 44.4 (20.7–65.3) 87.8 (69.3–111.2) .003
5-HIAA 3/5/11/10 141.3 (110.6–) 47.7 (43.1–213.4)* 336.1 (257.8–476.2)* 383.9 (279.5–717.0) .004
BA11/12 MHPG 4/6/11/10 91.8 (70.6–105.7)# 103.1 (63.9–111.2)** 437.1 (352.6–545.6)** 361.7 (216.5–636.3)# ,.001
5-HIAA 4/6/11/10 98.2 (85.4–189.7) 56.7 (35.3–78.5)** 238.5 (183.5–344.3)** 229.9 (168.9–328.3) ,.001
Cingulate gyrus MHPG 3/8/11/10 128.0 (58.8–) 126.0 (104.6–153.6)** 567.8 (258.4–739.3)** 336.9 (158.1–587.5) ,.001
DA 3/8/11/10 224.2 (7.9–) 55.5 (40.6–211.2)** 10.5 (3.8–13.0)** 9.6 (3.0–17.4) ,.001
5-HIAA 3/8/11/10 66.0 (34.5–)# 102.6 (58.5–191.8)** 357.3 (281.2–379.3)** 387.2 (313.7–475.7)# ,.001
Thalamus MHPG 3/11/11/10 159.2 (131.3–)# 148.3 (110.2–177.8)** 793.0 (628.6–1442.6)** 441.9 (244.1–1345.4)# ,.001
5-HIAA 3/11/11/10 673.7 (508.8–) 689.3 (412.4–895.8)** 1584.5 (1237.1–1952.8)** 1525.8 (1168.1–1946.8) ,.001
Basal ganglia
Caudate nucleus Adrenaline 2/11/7/6 533.3 (355.2–) 69.3 (42.7–151.0)* 268.5 (176.5–587.7)* 372.9 (185.7–743.0) .006
DA 3/16/11/10 4297.2 (1845.8–) 2395.2 (1178.5–2784.8)** 4721.2 (3403.8–6905.9)** 3965.1 (2987.2–4420.5) .003
HVA 3/16/11/10 2732.0 (2231.3–) 3145.6 (1522.7–3756.0)* 4681.2 (3714.5–5640.3)* 4372.3 (3564.4–6818.8) .014
5-HT 3/16/11/10 121.5 (33.1–) 55.8 (35.6–97.0)** 168.3 (139.5–230.2)** 240.0 (188.0–285.2) ,.001
5-HIAA 3/16/11/10 170.9 (76.6–) 217.6 (106.3–284.2)** 537.2 (362.3–727.8)** 579.6 (441.0–784.9) ,.001
Globus pallidus DOPAC 2/8/11/10 208.3 (28.0–) 131.7 (61.8–141.5)* 39.5 (19.5–85.8)* 20.1 (10.5–34.7) .004
5-HT 2/8/11/10 149.7 (89.7–) 97.4 (70.5–120.4)* 171.9 (117.6–207.7)* 161.8 (140.3–215.5) .022
5-HIAA 2/8/11/10 1009.2 (384.6–) 439.5 (329.9–978.8)* 984.5 (864.7–1407.3)* 1320.2 (1019.2–1614.4) .015
Putamen Adrenaline 2/8/11/10 390.4 (325.6) 135.0 (40.9–219.9)* 581.9 (187.2–1523.4)* 339.6 (100.7–797.8) .038
DOPAC 3/15/11/10 207.5 (165.1–) 611.6 (274.7–851.6) 421.9 (235.7–625.7) 202.2 (119.0–299.7) .008
5-HT 3/15/11/10 189.5 (43.9–) 77.8 (35.2–159.6)* 189.2 (153.9–219.8)* 219.7 (200.5–326.3) ,.001
5-HIAA 3/15/11/10 260.0 (231.7–) 372.7 (203.7–669.5)** 790.9 (638.7–1026.1)** 998.4 (781.9–1400.3) ,.001
Substantia nigra DA 2/14/11/10 164 (126.8–) 157.2 (89.0–292.4)** 572.7 (284.9–623.7)** 624.0 (295.7–936.8) ,.001
DOPAC 2/14/11/10 47.2 (47.1–) 58.0 (27.1–87.4)* 189.7 (80.3–211.0)* 47.1 (29.2–101.0) .005
HVA 2/14/11/10 3061.7 (2010.5–) 2421.8 (1995.7–3007.8)** 3799.4 (3461.0–4385.5)** 4331.0 (3241.6–5349.9) ,.001
5-HT 2/14/11/10 208.3 (167.6–) 364.1 (243.1–420.4) 487.2 (389.2–531.2) 461.0 (404.1–588.8) .009
Metencephalon
Locus coeruleus NA 0/10/10/10 – 88.6 (52.7–11.4)** 255.1 (171.9–400.7)** 347.3 (248.6–501.8) ,.001
MHPG 0/10/10/10 – 201.8 (151.8–259.5)* 429.6 (304.6–530.7)* 572.4 (158.9–836.2) .032
DOPAC 0/10/10/10 – 12.3 (8.1–19.2)** 39.0 (23.6–71.3)** 55.5 (33.1–98.6) ,.001
HVA 0/10/10/10 – 730.2 (482.0–1003.5) 1009.7 (905.7–1443.4) 1351.0 (1195.0–1482.2) ,.001
(Continued )
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Table 2
Comparison of postmortem concentrations between the groups (Continued )
Brain region Compound N
DS
(n 5 4)
DS1AD
(n 5 17)
EOAD
(n 5 11)
Controls
(n 5 10) P value
Cerebellum Adrenaline 0/7/4/6 – 36.4 (34.7–44.5)* 6.6 (3.6–12.7)* 21.4 (10.3–50.2) .017
MHPG 2/9/11/10 124.6 (100.3–) 101.1 (85.2–148.6)* 421.1 (232.5–708.2)* 518.1 (386.8–713.4) .001
DA 2/9/11/10 32.1 (8.4–) 15.5 (12.2–22.1)** 3.6 (1.5–8.6)** 3.6 (3.2–5.4) ,.001
DOPAC 2/9/11/10 35.1 (6.4–) 16.4 (11.3–26.8)* 8.2 (5.8–11.1)* 8.0 (6.0–8.3) .005
5-HT 2/9/11/10 66.5 (22.2–) 25.0 (14.5–34.9)** 4.6 (2.1–9.1)** 2.6 (2.3–6.8) ,.001
5-HIAA 2/9/11/10 30.8 (21.9–) 41.7 (33.8–56.5)** 206.0 (92.8–301.4)** 98.5 (73.7–207.2) ,.001
Abbreviations: AD, Alzheimer’s disease; BA, Brodmann area; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; DA, dopamine; DS, Down syndrome
without neuropathologic AD diagnosis; DS1AD, Down syndrome with neuropathologic AD diagnosis; DOPAC, 3,4-dihydroxyphenylacetic acid; EOAD,
early-onset Alzheimer’s disease; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.s., not significant.
NOTE. Monoamines and metabolites (ng/g tissue) are expressed as median (50%) with the interquartile range (25%–75%) between brackets. Kruskal-Wallis
tests were used to compare the four groups. If P, .05, post hocMann-WhitneyU tests were performed. After all analyses had been conducted, we accounted for
multiple comparisons by performing the Benjamini-Hochberg procedure. Here, we provide P values (Kruskal-Wallis) that remained significant after correction
(P, .015). Those in italics are no longer regarded significant but are nevertheless provided since the post hocMann-WhitneyU tests remained significant in the
Benjamini-Hochberg procedure. Post hoc comparisons were performed for DS vs. controls (#P , .015) and DS1AD vs. EOAD (*P , .015; **P,.001). The
accompanying ratios and the nonsignificant comparisons are provided in the supplementary material (Supplementary Tables 1-3).
A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 99-111 105BA11/12, r 5 0.91, P , .001; hippocampus, r 5 0.86,
P 5 .001; thalamus, r 5 0.75, P 5 .007; and cerebellum,
r 5 0.78, P 5 .004) in the EOAD group; and 5-HT in the
globus pallidus (r 5 20.85, P 5 .002) in the control group.
Although the PMD range was the largest in the DS1AD
group, most significant correlations were observed in the
EOAD group with overall lower PMDs (range: 2.8–7 hours).
Although an effect of PMDs cannot be ruled out, our main
findings do not appear to be evidently affected by PMDs.
3.1.1. Noradrenergic system
Between groups, NA differed significantly in the BA22,
amygdala, and LC. Specifically, NA levels were not altered
between DS and DS1AD, but lower in DS1AD compared
with EOAD (amygdala and LC, Table 2). This pattern was
more pronounced for MHPG (Fig. 2). Compared with
EOAD, DS1AD presented significantly lower MHPG levels
in the LC, cortical (BA7, BA9/10/46, and BA22) and limbic
projection areas (amygdala, hippocampus, BA11/12, cingu-
late gyrus, and thalamus), and cerebellum. Consequently, the
MHPG:NA ratio was consistently lower in DS1AD (BA9/
10/46, BA22, hippocampus, BA11/12, cingulate gyrus, thal-
amus, and cerebellum), indicating a reduced noradrenergic
turnover. Moreover, MHPG was significantly lower in DS
compared with controls (Fig. 2) for BA17, BA22, hippocam-
pus, BA11/12, and thalamus. Neither NA nor MHPG levels
differed significantly in the basal ganglia, whereas adrena-
line levels were lower in the caudate nucleus and putamen
and higher in the cerebellum in DS1AD (vs. EOAD). Taken
together, the noradrenergic system—particularly MHPG—
was strongly impaired in DS (vs. controls) and DS1AD
(vs. EOAD).
3.1.2. Dopaminergic system
No significant differences were observed for DS versus
DS1AD and DS versus controls. Compared with EOAD, bidi-
rectional dopaminergic changes became evident in DS1AD:
DA levels were significantly higher in the BA9/10/46, BA22,cingulate gyrus, and cerebellum and lower in the basal ganglia
(caudate nucleus and SN). Similarly, in DS1AD (vs. EOAD),
HVA was reduced in the caudate nucleus and SN. Conse-
quently, the HVA:DA ratio, indicative of dopaminergic turn-
over, was consistently lower in DS1AD (vs. EOAD) in
cortical areas (BA7, BA9/10/46, and BA22), limbic regions
(BA11/12, cingulate gyrus, and thalamus), and the cerebellum.
In contrast, the HVA:DA ratio was increased in the SN. The
pattern for DOPAC was bidirectional as well: values were
decreased in the SN andLC and increased in the globus pallidus
and cerebellum. The DOPAC:DA ratio was significantly lower
in the BA9/10/46, BA22, cingulate gyrus, and LC for DS1AD
versus EOAD. In short, the dopaminergic systemwas evidently
affected in DS1AD with higher DA levels (and thus lower
HVA:DA and DOPAC:DA ratios) in cortical areas, limbic re-
gions, and the cerebellum and lower DA and HVA levels in
the basal ganglia.
3.1.3. Serotonergic system
5-HTand 5-HIAA did not differ significantly between DS
and DS1AD. 5-HIAA levels in the cingulate gyrus and the
5-HIAA:5-HT ratio in the (pre)frontal cortex were signifi-
cantly lower in DS than in controls. Compared with
EOAD, 5-HT levels in DS1AD were significantly lower
in the amygdala and basal ganglia (caudate nucleus, globus
pallidus, and putamen) and higher in the (pre)frontal cortex
and cerebellum. In comparison with EOAD, 5-HIAA was
consistently lower in DS1AD, namely in cortical areas
(BA9/10/46, BA22), limbic system (amygdala, hippocam-
pus, BA11/12, cingulate gyrus, and thalamus), the basal
ganglia (caudate nucleus, globus pallidus, and putamen),
and the cerebellum. Similarly, the 5-HIAA:5-HT ratio was
reduced in the BA9/10/46, BA22, BA11/12, and cerebellum
in DS1AD versus EOAD, thus indicating an overall
decreased serotonergic turnover in DS1AD. In summary,
a serotonergic deficit became apparent in DS1AD, with a
pronounced overall reduction in 5-HIAA levels (and thus a
reduced 5-HIAA:5-HT ratio) as compared with EOAD.
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A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 99-111106Finally, the HVA:5-HIAA ratio, indicating serotonergic
inhibition on dopaminergic neurotransmission, clearly
differed between groups. Apart from a significantly higher
HVA:5-HIAA ratio in the cingulate gyrus in DS (vs. con-
trols), significance was, again, observed for the DS1AD
versus EOAD comparison. The ratio was invariably higher
in DS1AD for cortical regions (BA9/10/46 and BA22),
limbic system (amygdala, hippocampus, BA11/12, and
cingulate gyrus), and the cerebellum, suggestive of a
reduced serotonergic inhibition on the dopaminergic system.3.2. Monoaminergic characterization of (paired) CSF/
plasma samples
Samples of 225 DS individuals were included in analysis
(Fig. 1). Paired samples were available for 68 individuals
and plasma-only samples for 157 cases. Tables 3 and 4,
respectively, show the study group characteristics and
monoaminergic concentrations. The accompanying ratios are
provided in the supplementary material, Supplementary
Table 4. Remarkably, CSF/plasma concentrations did not differ
between the three groups apart from DOPAC levels in CSF
(medication-free subpopulation) and plasma (total population
and medication-free subpopulation). DOPAC levels were
consistently higher in DS1AD compared with DS (CSF
medication-free, P5 .001; plasma total, P, .001; and plasma
medication-free, 0.002) but did not differ for the DS versus
DS1pAD and DS1pAD versus DS1AD comparisons. Simi-
larly, plasma HVA (total), plasma 5-HIAA (total), and CSF
DOPAC:DA (medication-free) were higher in DS1AD versus
DS. In contrast, CSF HVA:5-HIAA (total) was decreased in
DS1AD. Moreover, DA (r 5 20.31, P 5 .012), DOPAC
(r 5 10.71, P , .001), MHPG (r 5 10.70, P , .001), and
adrenaline (r 5 10.49, P , .001) correlated significantly in
CSF and plasma (paired samples, total population). Groups
differed in age with DS1AD logically being the oldest.
DOPAC (CSF, r 5 10.362, P 5 .002; plasma, r 5 10.386,
P , .001), HVA (plasma, r 5 10.169, P 5 .011), and 5-
HIAA (CSF, r 5 10.365, P 5 .002; plasma, r 5 10.345,
P , .001) correlated significantly with age. After exclusion
of individuals younger than 45 years, that is, resembling the
elderly DS cohort in our previously published serum study
[12], comparison between DS (CSF/plasma, n 5 8; plasma-
only, n 5 34), DS1pAD (CSF/plasma, n 5 11; plasma-only,
n 5 31), and DS1AD (CSF/plasma, n 5 16; plasma-only,
n 5 38) yielded no significant monoaminergic differences,
again suggesting that DOPAC changes most likely relate to ag-
ing rather than dementia status.4. Discussion
Monoaminergic profiles were evaluated in 15 postmor-
tem brain regions and (paired) CSF/plasma samples. In
brain, pronounced noradrenergic, dopaminergic, and seroto-
nergic differences were found for DS1AD versus EOAD
and to a lesser extent for DS versus controls (primarily
Table 4
Comparison of CSF/plasma concentrations between the groups
Compound CSF or plasma Total or medication free N DS DS1pAD DS1AD P value
NA CSF Total 37/13/18 2.8 (0.9–5.5) 1.4 (0.6–4.9) 1.8 (0.8–5.6) n.s.
Medication free 21/7/10 2.8 (1.0–6.9) 1.4 (0.6–4.7) 1.4 (0.8–5.5) n.s.
Plasma Total 145/35/37 0.4 (0.2–0.9) 0.6 (0.2–0.9) 0.6 (0.4–1.1) n.s.
Medication free 90/16/15 0.5 (0.2–1.0) 0.4 (0.1–0.7) 0.4 (0.2–1.0) n.s.
Adrenaline CSF Total 35/13/16 0.5 (0.3–0.9) 0.7 (0.3–1.3) 0.4 (0.3–1.2) n.s.
Medication free 20/7/10 0.7 (0.3–1.0) 0.8 (0.2–2.1) 0.4 (0.4–1.2) n.s.
Plasma Total 147/35/39 2.9 (1.9–4.2) 2.6 (1.9–4.0) 3.3 (1.4–4.3) n.s.
Medication free 92/17/16 2.9 (2.0–4.0) 3.0 (2.0–4.2) 2.7 (1.2–3.9) n.s.
MHPG CSF Total 37/13/18 30.2 (21.5–44.6) 24.0 (18.8–40.0) 22.4 (19.6–46.0) n.s.
Medication free 21/7/10 31.1 (21.8–45.0) 24.0 (15.9–41.1) 28.5 (20.7–43.4) n.s.
Plasma Total 149/36/40 76.2 (51.2–102.4) 70.9 (50.4–111.6) 75.6 (55.3–114.4) n.s.
Medication free 93/17/16 77.3 (51.5–100.6) 70.4 (45.5–119.3) 63.0 (47.9–107.5) n.s.
DA CSF Total 37/13/18 0.6 (0.4–0.9) 0.5 (0.2–0.7) 0.6 (0.3–1.2) n.s.
Medication free 21/7/10 0.6 (0.4–0.9) 0.6 (0.3–1.0) 0.8 (0.4–1.3) n.s.
Plasma Total 149/35/40 0.5 (0.3–1.0) 0.5 (0.3–1.1) 0.7 (0.3–1.3) n.s.
Medication free 93/16/16 0.5 (0.3–1.0) 0.6 (0.4–1.1) 0.7 (0.4–1.9) n.s.
DOPAC CSF Total 37/13/18 0.6 (0.4–1.3) 1.2 (0.6–2.7) 1.7 (0.7–3.3) .033
Medication free 21/7/10 0.5 (0.4–1.0)xx 0.9 (0.5–1.5) 2.8 (1.1–5.6)xx .003
Plasma Total 149/36/40 2.7 (1.9–4.1)xx 3.1 (2.6–4.3) 4.3 (3.0–6.2)xx ,.001
Medication free 93/17/16 2.5 (1.9–3.6)x 3.1 (2.7–3.6) 5.3 (2.9–6.2)x .004
HVA CSF Total 37/13/18 54.6 (40.5–67.7) 55.1 (43.3–74.8) 55.3 (33.3–67.3) n.s.
Medication free 21/7/10 56.3 (41.5–64.1) 46.5 (35.2–79.5) 56.4 (33.1–67.2) n.s.
Plasma Total 149/36/40 9.4 (7.5–11.6)x 10.3 (7.4–12.7) 10.6 (8.7–15.0)x .039
Medication free 93/17/16 9.5 (7.4–12.2) 10.5 (7.6–13.0) 9.9 (8.5–14.2) n.s.
5-HT CSF Total 11/4/6 0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.1 (0.1–0.2) n.s.
Medication free 6/2/2 0.1 (0.1–0.2) 0.1 (0.1–) 0.1 (0.0–) n.s.
Plasma Total 149/36/40 9.5 (3.9–20.3) 11.1 (2.4–20.8) 9.7 (5.2–17.2) n.s.
Medication free 93/17/16 12.4 (7.1–25.0) 17.3 (8.0–28.6) 10.6 (8.4–20.7) n.s.
5-HIAA CSF Total 37/13/18 24.9 (18.1–28.9) 26.5 (21.5–35.4) 28.9 (23.2–34.3) n.s.
Medication free 21/7/10 26.6 (22.6–29.7) 26.5 (22.0–36.1) 33.2 (25.2–38.4) n.s.
Plasma Total 149/36/40 4.5 (3.7–5.4)x 4.7 (4.2–5.7) 5.0 (4.1–6.6)x .020
Medication free 93/17/16 4.5 (3.6–5.4) 5.3 (4.2–6.5) 4.9 (3.6–6.7) n.s.
Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; DA, dopamine; DS, Down syn-
drome without (clinical) dementia; DS1pAD, Down syndrome with prodromal AD; DS1AD, DS with diagnosed AD dementia; DOPAC, 3-4-
dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.s., not significant.
NOTE. Concentrations of monoamines and metabolites (ng/ml) are expressed as median (50%) with the interquartile range (25%–75%) between brackets.
The number (N) of samples is provided as certain compounds were not detectable in all samples. Kruskal-Wallis tests were performed to compare the three
groups. If P, .05, post hoc Mann-WhitneyU tests were performed. After all analyses had been conducted, we accounted for multiple comparisons by perform-
ing the Benjamini-Hochberg procedure. TheP values in italics are no longer regarded significant but are nevertheless provided since the post hocMann-Whitney
U tests remained significant in the Benjamini-Hochberg procedure. Post hoc comparisons were performed for DS vs. DS1pAD, DS vs. DS1AD (xP,.015 and
xxP ,.001) and DS1pAD vs. DS1AD. The accompanying ratios are provided in the supplementary material (Supplementary Table 4).
A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 99-111 107decreased MHPG levels), but not for DS versus DS1AD.
Similarly, CSF/plasma concentrations were virtually unal-
tered between the diagnostic DS groups.
In AD, studies have demonstrated LC neuronal
loss and reduced NA levels [21,35–39]. Noradrenergic
abnormalities have been implicated in DS too [40]. Here,
we demonstrate that the noradrenergic system was more
severely impacted in DS1AD versus EOAD and to a lesser
extent in DS versus non-DS controls. NA, MHPG, and the
MHPG:NA ratio were significantly reduced in most brain
areas, but not in the basal ganglia, which is in accordance
with the modest noradrenergic innervation of the basal
ganglia [35]. These results are also in agreement with earlier
studies reporting AD-related loss of LC neurons [21–23,36]
and reduced NA levels in various brain regions in DS1AD
compared with controls [16–20]. Our results demonstrate
that MHPG concentrations were most severely impacted inDS1AD (even more than in EOAD), but also in DS, thus
already before the neuropathological criteria for AD were
met.
DA is produced in the SN and ventral tegmental area
(VTA). In AD, a variable SN neuronal loss and diminished
DA levels have been described [41,42]. Whereas previous
studies did not report evident dopaminergic alterations in
DS [16,18], we found significantly increased DA levels (and
thus decreased HVA:DA and DOPAC:DA ratios) in cortical
areas, limbic regions and cerebellum, and a general
decrease in DA and HVA levels in the basal ganglia.
Indeed, lower DA levels in the caudate nucleus have been
reported in DS1AD versus EOAD and age-matched controls
[20]. Ascending dopaminergic projections are subdivided into
the nigrostriatal (from SN to striatum), mesolimbic (from
VTA to limbic system), and mesocortical (from VTA to cor-
tex) pathways [35]. Previously, a mild cell loss (though often
A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 99-111108not significant) in the SN, but also in the VTA, was found in
DS1AD compared with controls or younger counterparts
[23,36,43,44]. Our results may suggest a more severe
impairment of the nigrostriatal pathway (reduced DA levels
in caudate and SN), whereas the mesolimbic and
mesocortical pathways seem to be somewhat overactive,
possibly as a compensatory mechanism.
Concerning the serotonergic system, neuronal loss in the
dorsal raphe nuclei (5-HT production site) and reduced
levels of 5-HT and 5-HIAA in various brain regions have
been reported in AD and DS [16–18,35–37,39,45].
Compared with EOAD, we observed an even more severe
serotonergic impairment in DS1AD, presenting decreased
5-HIAA levels in 11 brain regions, while 5-HTwas reduced
in the amygdala and basal ganglia but increased in the (pre)
frontal cortex and cerebellum.
Interestingly, the DS and DS1AD groups showed remark-
ably similar monoaminergic profiles, although both groups
had different AD neuropathologic changes (low vs. high).
Importantly, the four DS cases with low AD neuropathologic
change already presented high amyloid burden (“ABC
scoring system” [25]: A2,B1,C2; A3,B1,C1; A3,B0,C0, and
A3,B0,C0, respectively). The third copy of the APP gene in
DS causes very early Ab overproduction and accumulation.
Deposition of Ab plaques occurs at ages as early as 12 years
and precedes tau pathology by many years [4]. Previously,
noradrenergic and serotonergic depletion was found to be
more severe in EOAD (mutations in APP or PSEN1/2,
promoting the amyloidogenic pathway) than in late-onset
AD [38]. Inverse relations between Ab accumulation and,
respectively, NA, DA, and 5-HT signaling have been
described [35,46]. This may suggest that the
monoaminergic system is particularly affected by (early)
Ab pathology, being altered long before full-blown AD
pathology is present. For a comprehensive summary about
the pathophysiological link between monoaminergic alter-
ations and AD pathology, see the review by Trillo et al. [35].
In the context of abnormal brain development,
monoamines were quantified in the frontal cortex of fetal
DS tissue (20 weeks) compared with controls. DA, 5-HT,
and 5-HIAA levels were significantly reduced in DS [47].
This suggests that monoamines are already impacted by tri-
somy 21 itself, which may be further impaired by progres-
sive Ab pathology during life. Compared with
age-matched controls, smaller brain volumes were found
in DS, among others of (pre)frontal cortex, hippocampus,
brainstem and cerebellum [48–50]. Fewer neurons
(cortical dysgenesis), altered neuronal distribution, and
reduced synaptic density were described in DS as well
[49]. Consequently, the compensatory reserve is likely to
be lower, which could result in a particularly early vulnera-
bility (functional impact) to additional neuropathology. To
differentiate between the alterations caused by trisomy 21
and AD pathology, respectively, future monoaminergic
studies should include DS samples without early Ab plaque
load. In the present study, we were unable to collect morethan four such cases (limiting the generalizability of the find-
ings in this group) because inclusion of DS cases in brain
banks, those without pathology in particular, is very limited.
In fact, the 21 cases analyzed here were obtained by three
large brain banks in a timeframe of 25 years. Contemporary
standardized (multicenter) brain banking efforts for DS are
thus imperative [51,52], focusing, among others, on the
collection of tissues with short(er) PMDs and good clinical
documentation. Although our main findings did not appear
to be evidently impacted by PMDs or psychoactive
medication use, such effects cannot be fully ruled out
because of the unavailability of DS tissue with low PMDs
and no psychoactive medication use.
The apparent lack of monoaminergic changes between
DS and DS1AD in the brain was also reflected in CSF/
plasma. The CSF/plasma groups were distinguished based
on a clinical dementia diagnosis, whereas from a neuropath-
ological perspective, the (amyloid) pathology is likely to be
quite comparable. In future studies, it would be useful to
relate monoaminergic values in DS to (in vivo) pathologic
staging, such as the CSF “AD profile” [11] or positron
emission tomography of Ab/tau [5]. Furthermore, mounting
evidence indicates an important role of neuroinflammation
in the pathogenesis of AD (in DS) [53], and it would thus
be valuable to look further than Ab and tau pathology and
examine the role of neuroinflammatory processes in mono-
aminergic alterations as well.
Surprisingly, the CSF/plasma results did not reflect
earlier results obtained in serum [12]. Whereas MHPG, for
instance, was evidently decreased in DS1AD serum,
MHPG levels were virtually unaltered in CSF/plasma. This
raises the question what causes this apparent discrepancy.
Our methodology has been validated [30], and the reported
values have orders of magnitude comparable to earlier
studies [14,15,54]. The—likely multifactorial—answer
remains to be elucidated, including the effect of
(alterations in) peripheral determinants, such as non-brain
sources of catecholamines (e.g., the sympathetic nervous
system is the main source of peripheral NA) and enzymes
involved in catecholaminergic turnover [55], as well as
(pre)analytical variables. O’Bryant et al. (2015) addressed
variables that can impact findings in blood, including
controllable variables (e.g., fasting status, tube type, centri-
fugation parameters, time from collection to freezing, and
freezing temperature) and uncontrollable variables (e.g.,
diet, activity level, comorbidities, andmedication). In partic-
ular, serum versus plasma, type of needle, additive in the
collection tubes, and presence of hemolysis may influence
the stability and detectability of biomarkers [56]. In CSF,
similar variables may impact biomarker levels [57,58].
Indeed, a few variables differ identifiably between our
serum and plasma studies, such as fasting status, storage
temperature, and storage time. Retrospectively identifying
the cause of the discrepancy is virtually impossible. New
initiatives should, therefore, systematically study the effect
of these variables on monoaminergic concentrations.
A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 99-111 109In conclusion, this study is the first to comprehensively
examine monoaminergic alterations in a unique collection
of postmortem brain regions and (paired) CSF/plasma sam-
ples of DS individuals. Despite various limitations described
previously, brain samples of DS1AD (vs. EOAD) revealed
generalized impairments in the noradrenergic and seroto-
nergic systems (overall decrease) and a bidirectional
dopaminergic change. For DS (vs. controls), significantly
decreasedMHPG levels were noted, though to a lesser extent
than for DS1AD (vs. EOAD). DS and DS1AD groups
showed remarkably similar monoaminergic profiles in the
brain. CSF/plasma concentrations did not differ between
the diagnostic DS groups either. The underlying cause for
the discrepancy with earlier serum findings remains unclear
and requires further study. To confirm whether the more
profound monoaminergic alterations in DS (vs. non-DS)
are indeed due to early Ab accumulation, (longitudinal)
studies using positron emission tomography imaging of
monoamines might provide a new avenue. For instance, neu-
roimaging of NA transporters in LC and key projection areas
using [11C]methylreboxetine [59] in relation to amyloid
deposition (e.g. [11C]Pittsburgh compound B) may be of
utmost importance in this respect. Moreover, to further
investigate disease progression, it would be valuable to
relate monoaminergic concentrations to CSF/plasma levels
of Ab and tau within individuals, for instance to the CSF
AD profile (low Ab42, high total-tau, and high
phosphorylated-tau) [11].Acknowledgments
This study was financially supported by the Gratama-
Stichting/Stichting Groninger Universiteitsfonds (2015–04),
the Research School for Behavioural and Cognitive Neurosci-
ences of the University of Groningen (RUG), Interuniversity
Poles of Attraction of the Belgian Federal Science Policy
Office (IAP network P7/16), the Belgian Foundation for
Alzheimer Research (SAO-FRA 15002), and the Carlos III
National Institute of Health of Spain (CM14/00029, PI13/
01532, PI11/02425 and PI14/01126) jointly funded by Fondo
Europeo de Desarrollo Regional, Union Europea, ‘Una man-
era de hacer Europa’, Fundacio Bancaria La Caixa, and
Marato de TV3 (20141210). This work has also been partially
supported by a grant from the Grifols Foundation, the
Generalitat de Catalunya (2014SGR-0235), and the Fundacio
Catalana de Sındrome de Down (FCSD). Further general
support was received from the Alzheimer Research Center
of the University Medical Center Groningen (UMCG), Neu-
rosearch Antwerp, and IBB. These public sponsors were not
involved in designing the study, collecting and interpreting
data, and writing the manuscript. The authors express their
gratitude to all individuals with Down syndrome and their
caregivers for their participation. We also thank the staff
members involved at the different centers, specifically
Michiel Kooreman (NBB) for his assistance with the post-
mortem material, Tinne Koninckx and Karen Sterck (IBB)for their immunohistochemical work, and Laia Mu~noz and
Raul Nu~nez (Sant Pau) for the laboratory and sample
handling.
Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.dadm.2017.11.001.RESEARCH IN CONTEXT
1 Systematic review: Alterations in monoamine neuro-
transmitters and metabolites have been implicated in
Alzheimer’s disease (AD) and Down syndrome (DS).
However, monoaminergic profiles have not been
extensively studied in cerebrospinal fluid (CSF) and
postmortem brain samples of DS with/without AD.
2 Interpretation: This is the first study to comprehen-
sively characterize DS samples with regard to AD
diagnosis. In CSF/plasma, monoaminergic levels
were not related to the clinical status of dementia in
DS. In brain, evident noradrenergic and serotonergic
deficits were found in DS1AD versus early-onset
AD patients, and to a lesser extent in DS versus
non-DS healthy controls. Our results reveal a rather
similar monoaminergic profile in both DS and
DS1AD, possibly caused by early trisomy 21–related
accumulation of amyloid b (Ab).
3 Future directions: Positron emission tomography
studies of monoaminergic neurotransmission may
reveal whether monoaminergic impairment in DS re-
lates to early Ab accumulation. Longitudinal studies
in relation to Ab imaging would be of utmost impor-
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